[EFFECT] Tharimmune, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

EFFECT

Rhea-AI Filing Summary

07/10/2025 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	July 9, 2025 5:00 P.M.

Form:

S-3

CIK:	0001861657
Company Name:	Tharimmune, Inc.
File Number:	333-288518

Source: View Original Filing on SEC EDGAR

Tharimmune Inc

NASDAQ:THAR

THAR Rankings

#10928 Ranked by Market Cap

N/A Ranked by Dividends

THAR Latest News

Jun 17, 2025

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

May 19, 2025

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

May 6, 2025

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 1, 2025

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Apr 30, 2025

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

THAR Latest SEC Filings

Jul 11, 2025

[S-8] Tharimmune, Inc. Employee Benefit Plan Registration

Jul 7, 2025

[Form 4] Tharimmune, Inc. Insider Trading Activity

Jul 7, 2025

[D] Tharimmune, Inc. SEC Filing

Jul 3, 2025

[S-3] Tharimmune, Inc. Shelf Registration Statement

Jun 24, 2025

[8-K] Tharimmune, Inc. Reports Material Event

THAR Stock Data

Market Cap 7.83M

Float 3.15M

Insiders Ownership 1.62%

Institutions Ownership 7.71%

Short Percent 1.88%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City BRIDGEWATER